Early clinical studies of personalized biomimetic nanovaccines, such as antigen-enriched cell membrane@PC7A platforms, demonstrate potent CD8+ T cell responses and tumor regression in preclinical models, underscoring their translational potential for overcoming therapy resistance [124]. The gene discussed is CD8A; the disease is neoplasm.